Anthony Lucci, MD

Articles by Anthony Lucci, MD

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

ByAttilla Soran,Berk Goktepe,Berkay Demirors,Serdar Ozbas,Efe Sezgin,Jamila Al-Azhri,Shruti Zaveri,S. Meas,Anthony Lucci, MD,Priscilla F. Mcauliffe, MD, PhD

April 21st 2024

How Heterogeneous Cell Populations, Cancer Cell Dormancy, and Minimal Residual Disease Influence the Natural History of Cancers

ByCarolyn Hall, PhD,Anthony Lucci, MD

Published: January 15th 2011 | Updated: November 11th 2020

The authors of “How Long Have I Had My Cancer, Doctor?” have addressed a question often contemplated by patients when they receive a diagnosis of cancer.

Latest Updated Articles

How Heterogeneous Cell Populations, Cancer Cell Dormancy, and Minimal Residual Disease Influence the Natural History of Cancers
Published: January 15th 2011 | Updated: November 11th 2020

Anthony Lucci, MD

Articles by Anthony Lucci, MD

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

How Heterogeneous Cell Populations, Cancer Cell Dormancy, and Minimal Residual Disease Influence the Natural History of Cancers

Latest Updated Articles

Trending on CancerNetwork

FDA Grants Approval to Teclistamab Combo in RRMM

The Evolving Landscape of Immunotherapy in Breast Cancer

Cadonilimab Yields 100% 24-Month OS in Recurrent Cervical Cancer Population

New Zenocutuzumab Findings Provide Hope for Targeting Rare NSCLC Subtypes

Comparable Ipilimumab/Nivolumab Outcomes Observed in Older RCC Population